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ABSTRACT
Hepatitis C virus (HCV) infection is one of the most common indications for liver trans-
plantation worldwide. Because of the existing organ shortage, adult-to-adult living do-
nor liver transplantation (LDLT) has become an important method of expanding the 
donor pool to meet the ever-increasing need. However, despite advantages such as the 
quality of the hepatic graft and the timing of the transplant, the exact role of LDLT in 
the treatment of HCV is still unclear. In this review, we aim to address some of these 
issues in an effort to highlight both the advantages and disadvantages, as well as to 
identify the main challenges, of using LDLT for treating patients with HCV infection.
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1. Introduction
Cirrhosis due to chronic hepatitis C virus (HCV) infec-
tion is one of the leading indications for liver transplan-
tation (LT) worldwide. Studies have shown that 75–85% of 
individuals infected with HCV develop chronic infection, 
which persists for at least 6 months after onset, with the 
rate of chronic infection varying by age, gender, race, 
and immune system status (1). Long-term infection has 
been associated with serious clinical sequelae, includ-
ing the development of hepatic fibrosis, cirrhosis of the 
liver, portal hypertension, and hepatocellular carcinoma 
(HCC) (2-4). Although the natural history of HCV infec-
tion is believed to be variable, it is estimated that up to 
20% of chronically infected individuals will develop liver 
cirrhosis over a 20- to 25-year period and that these indi-
viduals are at increased risk of developing HCC (2, 4). The 
magnitude of the impact of HCV becomes more evident 
if we consider that in the USA, there are nearly 10,000 
deaths annually due to HCV-related diseases, that HCV is 
responsible for nearly half of all HCC cases, and that the 
risk of developing HCC after the onset of cirrhosis is 3–4% 
per year (5). As a result, HCV-cirrhosis, which accounts 
for 35–40% of all cases of cirrhosis, has become the most 
common indication for LT in the USA (6).
Unfortunately, the increased need for livers is exacer-Hepat Mon. 2011;11(6):427-433
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bated by an organ shortage. In an effort to expand the 
limited donor pool, there has been increased focus on 
living donor liver transplantation (LDLT). In general, in-
dividuals with decompensated cirrhosis who meet the 
standard indications for LT, do not have any contrain-
dications, and have a Model for End-stage Liver Disease 
(MELD) score of 15 or higher are appropriate candidates 
for LDLT. Patients with a lower MELD score would not 
benefit from any form of LT, whereas those with a signifi-
cantly higher MELD score are potentially too sick to jus-
tify the use of a living donor liver graft (7). The problem, 
however, remains that the number of LDLT surgeries be-
ing conducted is low. One explanation for this is that the 
strenuous process that all potential living donors have 
to go through leads to a high rate of attrition among 
donors. In a report from 1 center, there was a 50% rate 
of attrition, mainly because of medical co-morbidities, 
psychosocial factors, financial issues, and the availabil-
ity of an organ from a deceased donor during the evalu-
ation process (8). Given the fact that in most centers only 
about one-third of the patients on the list may have an 
available living donor and of these, no more than half 
may undergo the evaluation successfully, only about 15% 
of patients on the list have the option of a LDLT (9). A 
second explanation is the severity of the donor surgery. 
Although living donors have an overall perception that 
donation is a positive event they do not regret partici-
pating in, with very few durable side effects, it is still a 
surgery that may lead to complications in 20–40% of do-
nors and carries a mortality risk of 0.3–0.5% for the do-
nor (10, 11). Two highly publicized donor deaths led to a 
significant drop in the number of centers in the USA per-
forming the procedure and the number of LDLT cases 
between 2001 and 2003 (12-14).
Overall, it is clear that the relationship between end-
stage liver disease secondary to HCV and LDLT is one of 
necessity. LDLT is a tremendous tour de force, both tech-
nically and ethically, presenting several challenges to the 
medical community because it is a unique procedure in 
which healthy people undergo a high-risk operation that 
has no benefit to their health. HCV infection is a leading 
indication for LT, and in the face of organ shortage, ev-
ery effort should be made to expand the donor pool to 
meet the needs of the patients with HCV infection. In ad-
dition, patients with HCC usually have a low MELD score, 
as their main problem and more imminent threat is not 
one of hepatic insufficiency, but rather one of advancing 
cancer. For these patients, the option of LDLT presents an 
opportunity for a timely cure. As a result, the need for liv-
ing donation is unlikely to decrease any time soon, and 
thus, it is important to determine the parameters for its 
proper role in the treatment of HCV infection.
2. LDLT for HCV: Issues and challenges
2.1. Graft quality
Compared to a full-sized deceased donor organ, a liv-
ing donor allograft has significantly less hepatic mass; 
this finding has led to the suggestion that the living do-
nor allograft should be treated as an “extended donor 
criteria” organ (15). A reason for concern is the small-for-
size syndrome, characterized by synthetic dysfunction, 
elevated aminotransferases, and prolonged cholestasis 
(16).  Small-for-size  syndrome  may  resolve  with  sup-
portive care and time, with transaminases returning to 
normal within days, but cholestasis can take weeks to re-
solve. The problem is that an allograft with transaminitis 
and cholestasis is particularly vulnerable to the acidosis, 
hypoglycemia, renal insufficiency or failure, and infec-
tions that may occur in the immediate postoperative 
period, leading to potentially irreversible damage that 
may prove deadly without retransplantation. It should 
also be stressed that small-for-size syndrome is not sole-
ly the result of transplanting a smaller volume graft, but 
is also the direct result of graft hemodynamics, as exces-
sive portal inflow, combined with compromised venous 
drainage of the partial graft, can lead to overperfusion 
and decreased function of the allograft (17-19). 
These  valid  concerns  are  outweighed  by  the  signifi-
cantly lower cold ischemia time of the living donor al-
lograft than the deceased donor organ, as well as the 
fact that the donor is a healthy, extensively screened in-
dividual (20). Assessment of potential donors includes 
both medical and psychosocial evaluations, performed 
by separate medical teams, to ensure that the donor is 
fully informed of the potential risks to themselves and 
the alternatives that the recipient may have in the event 
that the living donation does not proceed. The option to 
stop the process at any time is given in a way that would 
not affect the relationship of the donor with the recipi-
ent. The third portion of the evaluation involves the ana-
tomical assessment in which the quality, quantity, and 
anatomy of the donor’s liver is considered. This thor-
ough procedure leads to results at least as good as those 
achieved with organs from deceased donors, as we will 
see later in the paper.
2.2. Timing of transplantation
Determining  the  appropriate  timing  for  an  LT,  par-
ticularly for patients with HCV infection, requires a bal-
ancing act. In particular, the recipient has to be healthy 
enough to undergo the LT safely, but on the other hand 
sick enough so that the morbidity and mortality associ-
ated with the procedure do not outweigh the benefits 
(21). This is even more critical for patients with HCV in-
fection, in whom being able to avoid premature trans-
plant allows a delay in the recurrence of HCV in the new 
graft, which may prolong the recipient’s life, as well as 
allow time for the development of improved antiviral 
therapy. The principal advantage of LDLT is that it al-
lows the transplant team to choose the proper timing, 
thereby decreasing the risk of decompensation or death 
of a patient while on the waiting list, as well as providing 
flexibility, which can allow an attempt at pretransplant 
viral eradication (22, 23). If it is possible to proceed to Hepat Mon. 2011;11(6):427-433
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the transplant with a recipient negative for serum HCV 
RNA on therapy, then the percentage of posttransplant 
HCV recurrence after LDLT is very low (10%) and could 
essentially constitute a cure for HCV infection through 
transplantation (24). Furthermore, it is easier for a pa-
tient with a lower MELD score to tolerate a full-dose regi-
men for HCV eradication, and once viral eradication is 
achieved, one can proceed to the LDLT and achieve the 
optimal  result.  This  approach  could  potentially  cure 
about  40%  of  the  individuals  with  HCV  who  undergo 
LDLT (25).
2.3. Results of LDLT for HCV
Comparable data between LDLT and deceased donor 
liver transplantation (DDLT) for HCV have been reported 
using the UNOS database (26). In this large study com-
paring transplant recipients with chronic HCV who re-
ceived an LDLT (No. = 279) to those who received a DDLT 
(No. = 3955), the one-year survival rate was 87% in both 
groups and 2-year survival rate was 83% and 81% in the 
LDLT and DDLT groups, respectively (p = 0.68). Several 
other studies have shown similar results, either using 
UNOS data or single, large center experience, and dem-
onstrated  no  negative  impact  of  LDLT  on  the  results 
of liver transplantation for HCV infection (27-29). The 
Adult-to-Adult  Living  Donor  Liver  Transplantation  Co-
hort  Study  (A2ALL),  a  multicenter  study  of  275  liver 
transplants (181 LDLT and 94 DDLT) is one of the largest 
studies from which conclusions can be drawn (30). This 
study showed an overall statistically significant survival 
advantage for DDLT than for LDLT (82% vs. 74% at 3 years). 
However, a previous study showed poorer results when 
patients were separated into 3 groups: the cases of DDLT, 
the first 20 cases of LDLT performed at the center, and 
the remaining LDLT cases (31). In this study, although 
DDLT was more advantageous than LDLT (in the group 
of the first 20 LDLT cases), there was no difference in sur-
vival or rate of progression to fibrosis between the DDLT 
and the later LDLT cases. This raised the issue of center 
experience and the effect of the learning curve, as LDLT 
poses certain unique technical challenges such as vascu-
lar problems, biliary complications, and small-for-size 
syndrome (32, 33). Allowing for the importance of center 
experience may mean that LDLT for HCV infection may 
be at least as safe as DDLT. This still leaves the question of 
increased and more aggressive recurrence of HCV infec-
tion after LDLT than after DDLT.
2.4. HCV recurrence after LDLT
LDLT grafts have tremendous growth potential, as the 
graft regenerates 150,000 hepatocytes every second in 
the first week after transplantation and doubles in size 
within 4 weeks (34, 35). Although this is beneficial in re-
storing the necessary hepatocyte mass for the patient, 
it raises concerns regarding the effect that it may have 
on viral replication and the development of cholestatic 
hepatitis, a rapidly progressive and virulent form of HCV 
infection. Factors believed to work in favor of decreased 
HCV recurrence in LDLT than in DDLT include less acute 
cellular rejection with less immunosuppression; young-
er,  healthier  recipients;  fewer  African-American  LDLT 
recipients;  lower  HCV  posttransplantation  viral  load; 
and the opportunity for pretransplantation treatment 
to eradicate HCV or reduce the viral load (36-38). The 
factors that may be responsible for the more aggressive 
recurrence pattern sometimes seen with LDLT include 
increased HLA matching of the recipient with the do-
nor, especially since a significant number are relatives, 
and the very active hepatocyte regeneration, leading to 
increased  intrahepatocyte  HCV  proliferation  (39,  40). 
Moreover, experimental data suggest that liver regen-
eration  induces  low-density  lipoprotein  receptor  ex-
pression, which might facilitate HCV entrance into the 
hepatocytes (41, 42).
While 2 large studies have shown a similar incidence 
and severity of HCV recurrence between LDLT and DDLT 
recipients,  a  third  study  found  that  the  incidence  of 
cholestatic hepatitis is significantly greater in LDLT re-
cipients (26, 43-45). In an effort to resolve this discrepan-
cy, a careful comparison of protocol liver biopsies from 
23 LDLT and 53 DDLT recipients did not reveal significant 
differences in the degree of hepatic inflammation be-
tween the 2 groups over 3 years, and similar amounts of 
fibrosis in the LDLT group (43).
2.5. Treatment for HCV recurrence after LDLT
The fact that HCV may recur earlier and, potentially, 
in a more aggressive form after LDLT means that strate-
gies for HCV recurrence treatment are crucial. Treating 
DDLT-candidate patients with HCV infection is not usu-
ally feasible before the transplant to achieve viral reso-
lution  because  the  patients  cannot  tolerate  full-dose 
treatment  with  ribavirin  and  interferon,  given  their 
state of hepatic dysfunction. The alternative, aggressive, 
preemptive treatment after LT has not shown great suc-
cess (46, 47). LDLT has a distinct advantage over DDLT in 
the treatment of HCV recurrence because it is possible 
to treat recipients for HCV infection aggressively prior 
to the transplant, as they are more stable and can toler-
ate treatment. In addition, it is possible to arrange the 
timing of the transplant, so that it proceeds as soon as 
viral clearance is achieved. This has been shown to lead 
to a sustained virological response, and is thus the most 
definitive way to address the issue of recurrence (48).
2.6. Immunosuppression in LDLT for HCV infection
Another key issue in dealing with the conundrum of 
HCV recurrence after LT is the choice of immunosup-
pression.  Standard  posttransplant  immunosuppres-
sion  consists  of  a  calcineurin  inhibitor  (cyclosporine 
or tacrolimus), a tapering dose of corticosteroids, and 
in the majority of cases, an antiproliferating agent for Hepat Mon. 2011;11(6):427-433
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lymphocytes (mycophenolate mofetil or azathioprine). 
Antibodies to T cells (antithymocyte globulin) or to the 
interleukin-2 receptor (basiliximab) are less often used 
as induction agents, to either delay the initiation of the 
calcineurin  inhibitor  to  protect  renal  function,  or  to 
proceed with a very rapid steroid taper. Although clear 
data in favor of a single baseline immunosuppression 
regimen are limited, there is an agreement that more in-
tense immunosuppressive regimens can lead to worse 
outcomes. That is, patients receiving high bolus steroids 
and induction therapies in the form of antibodies to 
lymphocytes or interleukin-2 receptor are more likely 
to encounter HCV-induced graft failure and undergo a 
rapid progression to cirrhosis secondary to cholestatic 
hepatitis (49, 50). The problem is that these agents are 
also used to treat rejection, which has been associated 
with decreased survival in patients with HCV infection 
(51). The difficulties become even more apparent if we 
consider that differentiating between HCV recurrence 
and acute rejection on the basis of a biopsy examination 
may not be straightforward, as both have an element of 
portal inflammation and there is significant overlap.
The  above-mentioned  issues  in  finding  the  optimal 
immunosuppression  regimen  for  patients  with  HCV 
infection after LT are even more evident in the case of 
LDLT in which rejection is more prevalent. This leads to a 
balancing act between finding the appropriate amount 
of immunosuppression to avoid rejection on one hand, 
and  avoiding  uncontrolled  recurrence  of  HCV  on  the 
other hand (52). The main destabilizing factors are rap-
id changes in the level of immunosuppression, which 
leads to intense viral replication. Several strategies, such 
as rapidly tapering steroids or steroid-free immunosup-
pression  with  or  without  induction  antibodies,  have 
been employed to achieve this balance. However, stem-
ming from experience, the most sound practice appears 
to be the attainment of adequate immunosuppression 
to  avoid  the  incidence  of  rejection,  and  treating  any 
episodes that may occur with gradual increases in the 
existing regimen, rather than using bolus steroids or an-
tibodies (53).
2.7. Retransplantation and LDLT for HCV infection
The accelerated recurrence of HCV infection after LT 
raises the issue of whether to retransplant patients with 
graft failure. Results for retransplantation for HCV recur-
rence have been discouraging overall (54-56). Although 
many  studies  have  demonstrated  that  HCV-positive 
retransplant recipients have worse survival rates than 
HCV-negative recipients, there is conflicting data regard-
ing whether or not the cause of allograft failure in HCV-
positive patients influences survival. Most studies have 
actually demonstrated that recurrent HCV as a cause of 
allograft failure is less common and that allograft loss in 
HCV-positive recipients is much more likely to be caused 
by a nonfunctioning allograft, hepatic artery thrombo-
sis, and chronic rejection (57-59). Most data suggest that 
survival after retransplantation is poor in patients with 
HCV  infection,  even  in  those  retransplanted  for  non-
HCV-related indications (57, 60, 61).
To deal with this problem, arguments ranging from 
performing retransplantation for HCV-induced allograft 
failure early in its disease course to refusing retransplan-
tation to patients infected with HCV because it is unnec-
essary and futile have been forwarded (56, 60, 62). This 
is exactly where the use of LDLT raises important ethi-
cal and practical issues and offers certain possibilities 
with regard to the treatment of HCV-positive recipients. 
In particular, LDLT would not deplete the donor organ 
pool and would lead to the use of scarce deceased donor 
organs by patients who are awaiting primary liver trans-
plantation.  Despite  inferior  outcomes,  a  better  tactic 
may be to consider retransplantation for recurrent HCV 
in those patients whose primary transplant was an LDLT, 
as the initial allograft did not deplete the donor pool. 
2.8. HCC and LDLT
Patients with HCV infection have a higher rate of HCC, 
and since a pretransplant diagnosis of HCC has been 
shown to be an independent predictor of reduced over-
all patient survival beyond 90 days, timely LT is of the 
outmost importance (30). The most effective approach 
to reduce the dropout rate on the LT waiting list is to ex-
pand the number of available livers. A primary strategy 
towards this goal is the use of LDLT. Decision analyses, 
taking into account the risk of dropout while on the 
waiting list (4% per month), the expected survival of the 
recipient using the Milan criteria (70% at 5 years), and 
the risk for the donor (0.3–0.5% mortality), suggest that 
this is a cost-effective approach if the wait time exceeds 
7 months (63). Recently, MELD exception points for HCC 
were modified, as new data showed that former priori-
tization points for HCC were unfairly favoring access to 
DDLT for these patients. Compared to DDLT, LDLT offers 
the advantage of timely access to LT, while at the same 
time preserving the equity principle by not depleting 
the donor pool. Additionally, the development of live 
donation  has  stimulated  discussion  about  the  expan-
sion of the tumor burden limits for HCC patients. Since 
transplantation can be performed in a timely manner 
and with recent staging, there have been proposals that 
LDLT may be an option for patients whose tumor stage 
does not allow listing for DDLT. Deceased donor livers 
would then be allocated to patients with the best poten-
tial outcome (within Milan criteria and survival of 70% 
at 5 years), and living donation livers would benefit pa-
tients with a lower survival. Although this has a sound 
theoretical basis, data are not yet available to support 
utilizing  such  expanded  criteria  (64).  Furthermore, 
this policy of using LDLT for HCC patients outside the 
currently accepted criteria raises the question of what 
would happen if these patients require retransplanta-
tion. Overall, LDLT remains an important alternative for 
patients with HCV infection and HCC of small size, as it Hepat Mon. 2011;11(6):427-433
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provides access to LT in a timely manner.
2.9. Economic aspects of LDLT for HCV infection
In current times of fiscal constraint in most countries 
worldwide, any evaluation of a treatment ultimately re-
quires that society consider the financial burden associ-
ated with that treatment. Several studies have attempted 
to evaluate the extensive resources required for LDLT. A 
single center in New York found no increase in resources 
by examining the billing data (65). As financial cost has 
many different faces, a study using the A2ALL outcome 
data  showed  that  although  the  cost  increased  with 
LDLT, the survival of patients awaiting transplantation 
also increased (66). An increase of 0.5 quality-adjusted 
life years resulted from being on a waiting list, with the 
possibility of receiving both deceased and live donation, 
than from being on a waiting list with only the possibil-
ity of deceased donation. The cost of a transplant from 
the latter list was on average $151,613, whereas that from 
a list with both options was $208,149. Although LDLT rep-
resents a higher immediate cost, we must consider that 
there are factors that will counterbalance this cost. These 
include the learning curve that leads to the performance 
of LDLTs with fewer complications and quicker return to 
full activity for the donors, as well as the fact that we are 
able to transplant patients before they become too sick, 
thus affording a quicker recovery for the recipient. Ad-
ditional comprehensive outcomes studies are needed to 
obtain a more detailed picture of the financial aspects 
of LDLT.
3. Conclusion
The outcomes and patient survival after LDLT for treat-
ment of HCV infection appear to be comparable to those 
of patients undergoing DDLT. The main advantage for 
the recipient is a decrease in the waiting time, which 
can prove to be life saving. From a global perspective, 
the advantage becomes even more evident in countries 
with no history of DDLT and in which LDLT has proven 
to be an excellent way to increase the donor pool. How-
ever, concerns remain about the problem of aggressive 
HCV recurrence, as well as the safety of the donor. That 
these concerns have led a great number of centers to 
decide against retransplantation for patients with HCV 
recurrence, makes LDLT all the more important. This is 
because LDLT does not deplete the deceased donor pool, 
and hence, these patients should not be excluded if re-
transplantation is necessary. In addition, the continu-
ous increase in the number of patients with HCV infec-
tion worldwide means that this group of patients that 
present  a  challenge  to  the  health  system  cannot  and 
must not be ignored, irrespective of the difficulties in 
the management of their condition. It is imperative that 
these issues are addressed in a multicenter effort, such 
as the A2ALL study, and with careful long-term follow-
up.
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